Browse the evidence

PAP+semaglutide was associated with lower incident pulmonary hypertension (PH) at 1 year (RR:0.45) and at 3 years (RR:0.50), and lower mortality at 1 year (RR:0.35) and 3 years (RR:0.37).

Incorporating GLP-1 receptor agonists like semaglutide may enhance treatment outcomes for obese patients with OSA on PAP.

The increase in body protein mass due to the energy surplus was correlated with an increase in fat mass (r = 0.820, p = 0.002).

Increased body fat may play a role in promoting body protein mass gain.

Glucagon-like peptide 1 receptor agonists consistently reduce three-point major adverse cardiovascular events (MACE) in patients with overweight, obesity, and established cardiovascular disease (CVD) with and without diabetes.

Practitioners can consider glucagon-like peptide 1 receptor agonists as effective treatments for reducing cardiovascular events in eligible patients.

Semaglutide and tirzepatide improve symptoms and functional capacity in obesity-related heart failure of preserved ejection fraction and reduce worsening heart failure events.

Practitioners can use semaglutide and tirzepatide to improve heart failure symptoms in patients with obesity.

For the low-fat diet, income, leptin, education, low-density lipoprotein, and dietary adherence at baseline are significant predictors of weight loss success.

Practitioners should assess these factors when advising on low-fat diets.

Tirzepatid is being studied for its safety and efficacy as a treatment for obesity.

Practitioners should consider Tirzepatid as a potential treatment option for obesity.

Tirzepatid is being studied for its safety and efficacy as a treatment for obesity.

Practitioners should consider Tirzepatid as a potential treatment option for patients with obesity.

Obesity has a compelling influence on fertility and reproductive health.

Healthcare practitioners should consider the impact of obesity on reproductive health when treating patients.

Obesity in females is correlated with menstrual abnormalities, infertility, and complications during gestation.

Clinicians should assess reproductive health in obese female patients.

Tirzepatide has been approved by the FDA for type 2 diabetes in adults as a single dose weekly.

Practitioners can prescribe Tirzepatide for managing type 2 diabetes in adults.

Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity.

Practitioners should be aware of Tirzepatide's potential for treating obesity in clinical settings.

There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery.

Practitioners should consider integrating pharmacotherapy with lifestyle changes and surgical options for comprehensive obesity management.

GLP-1 agonists improve blood glucose profiles and reduce cardiovascular risk.

GLP-1 agonists can be recommended for improving glycemic control and reducing cardiovascular risks in diabetic patients.

Dual GIP/GLP-1 agonists are more effective in treating obesity than GLP-1 agonists alone.

Consider dual GIP/GLP-1 agonists for potentially better outcomes in obesity treatment.

Patients treated with semaglutide experienced a greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo, with an estimated treatment difference of 7.8 points (P < .001).

Semaglutide may be an effective treatment option for improving heart failure symptoms in obese patients.

Co-stimulation of GLP-1 with other receptors provides additional therapeutic benefits.

Combining GLP-1 therapy with other hormonal treatments may enhance effectiveness.

Behavioral support is necessary to maximize the benefits of incretin therapy.

Practitioners should integrate behavioral support strategies into incretin therapy plans.

Tirzepatide demonstrated a positive impact on the cardiovascular system.

Tirzepatide may be beneficial for patients with cardiovascular concerns related to diabetes.

GLP-1 receptor agonists (GLP-1RA) significantly reduce major adverse cardiovascular events (MACE) with a pooled hazard ratio of 0.86.

GLP-1RA can be recommended for reducing cardiovascular risks in patients with type 2 diabetes and obesity.

Both systolic blood pressure (SBP) and weight reductions are independently associated with reduced MACE risk.

Weight management and blood pressure control should be emphasized in treatment plans for these patients.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in obesity management is increasing.

Practitioners should be aware of the growing role of GLP-1 RAs in obesity treatment.

The combination of an amylin analog and other anti-obesity peptide drugs has demonstrated higher clinical efficacy in reducing body weight than monotherapy.

Combination therapies may be more effective for weight loss than single-drug treatments.

Treatment modalities for obesity include lifestyle modification, pharmacotherapy, and bariatric surgery.

Clinicians should consider a range of treatment options for obesity management.

Various treatment modalities, including GLP-1 agonists and dual GLP-1/GIP agonists, are reviewed for their effects on hepatic steatosis and fibrosis.

Practitioners should consider these treatment modalities for managing MASLD.